Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20221103 | 0.92 | BACE1 (0.43) | BACE1SMN1; SMN2NPC1RAB9APTAFR | |
| SCHEMBL15969314 | 0.86 | SMN1; SMN2 (0.40) | BACE1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15836739 | 0.84 | CYP3A4 (0.44) | ALDH1A1MEN1KMT2AUSP2CYP2C19 | |
| SCHEMBL26442429 | 0.83 | POLB (0.41) | SMN1; SMN2PTAFRALDH1A1USP2MAPT | |
| SCHEMBL15837085 | 0.83 | FASN (0.40) | BACE1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15836945 | 0.81 | PDK2 (0.46) | BACE1MEN1KMT2APDK2ALK | |
| SCHEMBL15837092 | 0.79 | CYP1A2 (0.42) | BACE1ALDH1A1PDK2CYP3A4HIF1A | |
| SCHEMBL204595 | 0.76 | PDK2 (0.43) | BACE1PDK2 | |
| SCHEMBL15982012 | 0.76 | PDK2 (0.35) | BACE1PDK2 | |
| SCHEMBL15836825 | 0.76 | NEK2 (0.46) | SMN1; SMN2ALDH1A1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139731-A1 | PROCESS FOR PREPARING MANNOSE DERIVATIVES | ENTEROME (FR) | 2023-05-04 | — | — | US | disclosed |
| US-20230139731-A1 | PROCESS FOR PREPARING MANNOSE DERIVATIVES | ENTEROME (FR) | 2023-05-04 | — | — | US | disclosed |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMA (US) | 2022-05-05 | — | — | US | disclosed |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2020021113-A1 | PROCESS FOR PREPARING MANNOSE DERIVATIVES | ENTEROME (FR) | 2020-01-30 | — | — | WO | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014100158-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | BACE1 1917/4885SMN1; SMN2 3742/4885NPC1 685/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | BACE1 1917/4885SMN1; SMN2 3742/4885NPC1 685/4885 |
| US-20230139731-A1 | PROCESS FOR PREPARING MANNOSE DERIVATIVES | C1R, CBR1, FUT8 | BACE1 2719/4885SMN1; SMN2 3147/4885NPC1 1258/4885 |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | DHPS, CFTR, FDPS | BACE1 2980/4885SMN1; SMN2 2744/4885NPC1 390/4885 |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | BACE1 1917/4885SMN1; SMN2 3742/4885NPC1 685/4885 |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | BACE1 1917/4885SMN1; SMN2 3742/4885NPC1 685/4885 |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | BACE1 1917/4885SMN1; SMN2 3742/4885NPC1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.